IRCCS Azienda Ospedaliero-Universitaria di Bologna

In a phase II trial (NCT04928820), 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT showed identical bone metastasis detection rates in prostate cancer patients with biochemical progression during ADT. Both scans detected equal numbers of bone lesions in 64% of patients, with PSMA PET/CT detecting more in 27% and bone scan plus CT detecting more in 9.1%. Inter-reader agreement was higher for PSMA PET/CT (96%) than for bone scan plus CT (82%).